Fostamatinib disodium
Sponsors
Rigel Pharmaceuticals, National Cancer Institute (NCI)
Conditions
Carcinoma, Non-Small-Cell LungCarcinoma, Renal CellColorectal NeoplasmsHead and Neck NeoplasmsImmune Thrombocytopenic PurpuraPheochromocytomaT Cell LymphomaWarm Antibody Autoimmune Hemolytic Anemia
Phase 2
Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma
CompletedNCT00798096
Start: 2009-03-31End: 2010-04-30Updated: 2016-09-19
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
CompletedNCT00923481
Start: 2009-04-30End: 2012-01-31Updated: 2015-09-30
Phase 3
A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
CompletedNCT02076412
Start: 2015-01-31End: 2016-08-31Updated: 2019-01-25
A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
CompletedNCT02076399
Start: 2014-07-14End: 2016-04-21Updated: 2019-02-12
Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
CompletedNCT02077192
Start: 2014-10-31End: 2020-06-02Updated: 2023-12-11
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA
CompletedNCT03764618
Start: 2019-04-24End: 2022-04-11Updated: 2023-05-25
A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Enrolling by invitationNCT04138927
Start: 2019-10-30End: 2024-04-30Target: 90Updated: 2022-03-17